The JAK inhibitor ruxolitinib abrogates immune hepatitis instigated by concanavalin A in mice

Therapeutics that impair the innate immune responses of the liver during the inflammatory cytokine storm like that occurring in COVID-19 are greatly needed. Much interest is currently directed toward Janus kinase (JAK) inhibitors as potential candidates to mitigate this life-threatening complication...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaker, Mohamed E., Hendawy, Omnia M., El-Mesery, Mohamed, Hazem, Sara H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363025/
https://www.ncbi.nlm.nih.gov/pubmed/34952468
http://dx.doi.org/10.1016/j.intimp.2021.108463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363025/
https://www.ncbi.nlm.nih.gov/pubmed/34952468
http://dx.doi.org/10.1016/j.intimp.2021.108463

Ejemplares similares